Akelos

Akelos

Biotechnology, 40 Park Ave, New York, 10016, United States, 1-10 Employees

akelosinc.com

  • facebook
  • twitter
  • LinkedIn

Who is AKELOS

Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the t...

Read More

map
  • 40 Park Ave, New York, New York, 10016, United States Headquarters: 40 Park Ave, New York, New York, 10016, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 7371; 8011

checked-icon Does something look wrong? Fix it. | View contact records from AKELOS

Akelos Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Akelos

Answer: Akelos's headquarters are located at 40 Park Ave, New York, 10016, United States

Answer: Akelos's official website is https://akelosinc.com

Answer: Akelos's revenue is Under $1 Million

Answer: Akelos's SIC: 7371; 8011

Answer: Akelos has 1-10 employees

Answer: Akelos is in Biotechnology

Answer: Akelos contact info: Phone number: Website: https://akelosinc.com

Answer: Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. The goal of Akelos is to address some of todays most pressing areas of unmet needs. Over 21 million adults suffer from Neuropathic Pain in the US alone, for which opioid medication is a common treatment. Associated costs exceed $90 billion/year in the US, and roughly 40 70% of people do not receive proper medical treatment and are at risk for either over or undertreatment. Akelos: Building New Frontiers to Address Neuropathic Pain Akelos is an innovative research-based biotechnology company founded to address the Opioid epidemic through opioid alternatives, with two drug candidates in pre-clinical development. Akelos has proudly entered into a research collaboration to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. Akelos holds an exclusive worldwide license with Columbia University and Cornell University and is working in collaboration with Weill Cornell Medicine. Researchers at Weill Cornell University and Columbia University have developed novel compounds for the treatment of neuropathic pain, resulting in intellectual property that is jointly owned by Cornell and Columbia. Akelos has licensed this intellectual property and is developing a treatment for neuropathic pain using the novel compounds.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access